利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

63 条记录 (耗时 0.022 秒)

    Calcification-resistant materials and methods of making same through use of multivalent cations
    42.
    发明授权
    Calcification-resistant materials and methods of making same through use of multivalent cations 失效
    通过使用多价阳离子，耐钙材料及其制备方法

    公开(公告)号：US5679112A

    公开(公告)日：1997-10-21

    申请号：US345658

    申请日：1994-11-28

    申请人： Robert J. Levy ,  Amnon Sintov

    发明人： Robert J. Levy ,  Amnon Sintov

    IPC分类号： A61L27/36 ,  A61L27/50 ,  A61L27/54 ,  C14C3/00 ,  A61F2/02

    CPC分类号： A61L27/50 ,  A61L27/3604 ,  A61L27/3687 ,  A61L27/54 ,  A61L2300/102 ,  A61L2300/21 ,  A61L2300/216 ,  A61L2300/40 ,  A61L2300/45 ,  A61L2400/02 ,  A61L2430/40 ,  Y10S128/08 ,  Y10S623/921

    摘要： Bioprosthetic materials, either natural or synthetic, are treated with trivalent iron cations, or salts, to prevent in vivo calcification. Such bioprosthetic materials include porcine aortic valve leaflets, bovine pericardium, aortic homografts, biocompatible elastomers, and the like which are intended for invasive, or in-dwelling use in a human or animal body. Simple incubation of the natural bioprosthetic materials in an iron ion-containing solution, such as aqueous FeCl.sub.3, particularly with the addition of an anticalcification agent, such as a diphosphonate, prior to implantation has been found to inhibit calcification of the biomaterial over a prolonged period, and to do so without adverse side effects. Incorporation of an iron-containing compound, with or without an additional anticalcification agent, into the formulation for polymers, such as polyurethane, has also been found to inhibit calcification with no adverse side effects.

    摘要翻译： 天然或合成的生物假体材料用三价铁阳离子或盐处理，以防止体内钙化。 这样的生物假体材料包括旨在用于人或动物体内的侵入性或住宅用的猪主动脉瓣瓣叶，牛心包膜，主动脉同种异体移植物，生物相容性弹性体等。 天然生物假体材料在含铁离子的溶液（如FeCl 3水溶液）中特别是在植入前特别是加入抗细胞剂如二膦酸盐的简单温育已被发现能够在长时间内抑制生物材料钙化 ，并且没有不利的副作用。 含有或不含额外抗氧化剂的含铁化合物掺入用于聚合物如聚氨酯的聚合物的制剂中也被发现抑制钙化而没有不利的副作用。

    Calcification-resistant synthetic biomaterials
    43.
    发明授权
    Calcification-resistant synthetic biomaterials 失效
    抗钙合成生物材料

    公开(公告)号：US5296583A

    公开(公告)日：1994-03-22

    申请号：US910941

    申请日：1992-07-09

    申请人： Robert J. Levy

    发明人： Robert J. Levy

    IPC分类号： A61L27/00 ,  A61L27/14 ,  A61L27/18 ,  A61L27/36 ,  A61L27/50 ,  A61L33/00 ,  C08G59/14 ,  C08L101/00 ,  C08L101/02 ,  C08G18/38

    CPC分类号： C08G59/1488 ,  A61L27/14 ,  A61L27/18 ,  A61L27/50 ,  A61L27/54 ,  A61L33/0011 ,  A61L2400/02

    摘要： Synthetic biomaterials are provided with irreversibly bound amino diphosphonate, polyphosphonate, or other anticalcification agent to prevent in vivo calcification. Such biomaterials include biocompatible elastomers such as polyurethane and/or polydimethylsiloxane, and the like which are intended for invasive, or in-dwelling use in a human or animal body. Illustratively, reaction conditions utilizing bi- or polyfunctional epoxides result in epoxide bridge incorporation of the anticalcification agent to the biomaterial elastomer.

    摘要翻译： 提供合成生物材料具有不可逆结合的氨基二膦酸盐，聚膦酸盐或其它抗细胞剂以防止体内钙化。 这样的生物材料包括生物相容性弹性体，例如聚氨酯和/或聚二甲基硅氧烷等，其旨在用于人或动物体内的侵入性或住宅用途。 说明性地，使用双官能或多官能环氧化物的反应条件导致抗氧化剂与生物材料弹性体的环氧桥结合。

    Sustained delivery of polyionic bioactive agents
    47.
    发明授权
    Sustained delivery of polyionic bioactive agents 失效
    持续输送聚离子生物活性剂

    公开(公告)号：US06395029B1

    公开(公告)日：2002-05-28

    申请号：US09234011

    申请日：1999-01-19

    申请人： Robert J. Levy

    发明人： Robert J. Levy

    IPC分类号： A61F200

    CPC分类号： B82Y5/00 ,  A61F2/82 ,  A61F2250/0098 ,  A61K47/6455 ,  A61K47/6937 ,  A61K48/00 ,  A61L17/145 ,  A61L31/16 ,  A61L2300/258 ,  A61L2300/416 ,  A61L2300/606

    摘要： The invention relates to compositions and methods for delivering a polyionic bioactive composition such as a nucleic acid to a tissue of an animal. The compositions of the invention include compositions which comprise a matrix comprising the polyionic bioactive agent and wherein at least most of the polyionic bioactive agent at the exterior portion of the matrix is present in a condensed form. The invention also includes methods of making such compositions, including particles, devices, bulk materials, and other objects which comprise, consist of, or are coated with such compositions. Methods of delivering a polyionic bioactive agent to an animal tissue are also described. The invention further includes a method of storing a nucleic acid.

    摘要翻译： 本发明涉及用于将聚离子生物活性组合物例如核酸递送至动物组织的组合物和方法。 本发明的组合物包括包含基质的组合物，所述基质包含聚离子生物活性剂，并且其中基质外部部分的至少大部分聚离子生物活性剂以浓缩形式存在。 本发明还包括制造这样的组合物的方法，包括颗粒，装置，散装材料以及其它包含这些组合物的组合物，或由这些组合物涂覆的物体。 还描述了将聚离子生物活性剂递送到动物组织的方法。 本发明还包括存储核酸的方法。

    System for controlled release of antiarrhythmic agents
    48.
    发明授权
    System for controlled release of antiarrhythmic agents 失效
    用于控制释放抗心律失常药物的系统

    公开(公告)号：US5387419A

    公开(公告)日：1995-02-07

    申请号：US37810

    申请日：1993-03-26

    申请人： Robert J. Levy ,  Amnon Sintov

    发明人： Robert J. Levy ,  Amnon Sintov

    IPC分类号： A61K9/00 ,  A61K9/70

    CPC分类号： A61K9/0024 ,  A61K9/7007 ,  Y10S514/821

    摘要： A system for controlled release, site-specific delivery of therapeutic agents, particularly myocardial agents such as antiarrhythmic agents, comprises a biocompatible polymeric matrix with an incorporated therapeutic agent for direct placement at the epicardium. Advantageously, the dosage form can be fabricated in such a manner as to tailor the release characteristics as required by the nature of the physical condition desired to be treated. In a specific illustrative embodiment, lidocaine, an antiarrhythmic depressant, is incorporated in polyurethane by a unique method which permits drug-loading of the polymeric matrix from about 5% up to 40% by weight, with about 25% to 30% in a preferred embodiment. A novel FeCl.sub.3 catalyst causes the polyurethane to polymerize despite the presence of drug in the polymeric matrix mixture.

    摘要翻译： 用于受控释放，特定地点递送治疗剂，特别是心肌药物如抗心律失常剂的系统包括具有用于直接置于心外膜的并入治疗剂的生物相容性聚合物基质。 有利地，剂型可以按照所需待处理的物理条件的性质来定制释放特性的方式制造。 在具体的说明性实施方案中，通过独特的方法将利多卡因，抗心律失常抑制剂掺入聚氨酯中，其允许聚合物基质的药物加载量为约5％至40％重量，优选的为约25％至30％ 实施例。 尽管在聚合物基质混合物中存在药物，但新型FeCl 3催化剂使聚氨酯聚合。